Discovery of orally available runt-related transcription factor 3 (RUNX3) modulators for anticancer chemotherapy by epigenetic activation and protein stabilization

Journal of Medicinal Chemistry

Volumn 58, Issue 8, 2015, Pages 3512-3521

  Yang, Jee Sun ^a   Lee, Chulho ^a   Cho, Misun ^a   Kim, Hyuntae ^a   Kim, Jae Hyun ^a   Choi, Seonghwi ^a   Oh, Soo Jin ^b   Kang, Jong Soon ^b   Jeong, Jin Hyun ^a   Kim, Hyun Jung ^c   Han, Gyoonhee ^a  

^a Yonsei University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 [3 (2 ETHOXYPHENYL)PROPYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL] N HYDROXYACRYLAMIDE; AGENTS AFFECTING PROTEIN METABOLISM; ANTINEOPLASTIC AGENT; BUSPIRONE; EPIGENETIC READER DOMAIN INHIBITOR; HISTONE DEACETYLASE INHIBITOR; N HYDROXY 3 [1 [3 (3 METHOXYPHENYL)PROPYL] 2 OXO 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; N HYDROXY 3 [2 OXO 1 (QUINOLIN 2 YLMETHYL) 1,2 DIHYDROPYRIDIN 3 YL]ACRYLAMIDE; PYRIDONE DERIVATIVE; RUNT RELATED TRANSCRIPTION FACTOR 3 MODULATOR; SMALL MOLECULE TRANSPORT AGENT; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ELIMINATION HALF-LIFE; EPIGENETICS; EXPERIMENTAL NEOPLASM; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC50; MALE; METABOLIC STABILITY; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ACETYLATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; MICROSOME; MOUSE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ACETYLATION; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICROSOMES; PROTEIN STABILITY; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTIONAL ACTIVATION;

EID: 84928494317     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00062     Document Type: Article

References (36)

1. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 2012, 11, 384-400
2. Fleming, C. L.; Ashton, T. D.; Gaur, V.; McGee, S. L.; Pfeffer, F. M. Improved synthesis and structural reassignment of MC1568: a class IIa selective HDAC inhibitor J. Med. Chem. 2014, 57, 1132-1135
3. McKinsey, T. A. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart J. Mol. Cell. Cardiol. 2011, 51, 491-496
4. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46, 5097-5116
5. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 2008, 51, 1505-1529
6. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 2009, 27, 5459-5468
7. Nakagawa, M.; Oda, Y.; Eguchi, T.; Aishima, S.; Yao, T.; Hosoi, F.; Basaki, Y.; Ono, M.; Kuwano, M.; Tanaka, M.; Tsuneyoshi, M. Expression profile of class I histone deacetylases in human cancer tissues Oncol. Rep. 2007, 18, 769-774
8. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future Nat. Rev. Drug Discovery 2006, 5, 37-50
9. Vigushin, D. M.; Coombes, R. C. Targeted histone deacetylase inhibition for cancer therapy Curr. Cancer Drug Targets 2004, 4, 205-218
10. Popovic, R.; Licht, J. D. Emerging epigenetic targets and therapies in cancer medicine Cancer Discovery 2012, 2, 405-413
11. Wilting, R. H.; Dannenberg, J. H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance Drug Resist. Updates 2012, 15, 21-38
12. Ivanov, M.; Kacevska, M.; Ingelman-Sundberg, M. Epigenomics and interindividual differences in drug response Clin. Pharmacol. Ther. 2012, 92, 727-736
13. New, M.; Olzscha, H.; La Thangue, N. B. HDAC inhibitor-based therapies: Can we interpret the code? Mol. Oncol. 2012, 6, 637-656
14. Rius, M.; Lyko, F. Epigenetic cancer therapy: rationales, targets and drugs Oncogene 2012, 31, 4257-4265
15. Singh, B. N.; Zhang, G.; Hwa, Y. L.; Li, J.; Dowdy, S. C.; Jiang, S. W. Nonhistone protein acetylation as cancer therapy targets Expert Rev. Anticancer Ther. 2010, 10, 935-954
16. Tang, J.; Yan, H.; Zhuang, S. Histone deacetylases as targets for treatment of multiple diseases Clin. Sci. 2013, 124, 651-662
17. Chuang, L. S.; Ito, Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors Oncogene 2010, 29, 2605-2615
18. Li, Q. L.; Ito, K.; Sakakura, C.; Fukamachi, H.; Inoue, K.; Chi, X. Z.; Lee, K. Y.; Nomura, S.; Lee, C. W.; Han, S. B.; Kim, H. M.; Kim, W. J.; Yamamoto, H.; Yamashita, N.; Yano, T.; Ikeda, T.; Itohara, S.; Inazawa, J.; Abe, T.; Hagiwara, A.; Yamagishi, H.; Ooe, A.; Kaneda, A.; Sugimura, T.; Ushijima, T.; Bae, S. C.; Ito, Y. Causal relationship between the loss of RUNX3 expression and gastric cancer Cell 2002, 109, 113-124
19. Tsang, Y. H.; Lamb, A.; Chen, L. F. New insights into the inactivation of gastric tumor suppressor RUNX3: the role of H. pylori infection J. Cell. Biochem. 2011, 112, 381-386
20. Bae, S. C.; Lee, Y. H. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation Gene 2006, 366, 58-66
21. Li, Q. L.; Kim, H. R.; Kim, W. J.; Choi, J. K.; Lee, Y. H.; Kim, H. M.; Li, L. S.; Kim, H.; Chang, J.; Ito, Y.; Youl Lee, K.; Bae, S. C. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer Biochem. Biophys. Res. Commun. 2004, 314, 223-228
22. Jin, Y. H.; Jeon, E. J.; Li, Q. L.; Lee, Y. H.; Choi, J. K.; Kim, W. J.; Lee, K. Y.; Bae, S. C. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation J. Biol. Chem. 2004, 279, 29409-29417
23. Lee, S. H.; Kim, J.; Kim, W. H.; Lee, Y. M. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells Oncogene 2009, 28, 184-194
24. Wang, C.; Liu, Z.; Woo, C. W.; Li, Z.; Wang, L.; Wei, J. S.; Marquez, V. E.; Bates, S. E.; Jin, Q.; Khan, J.; Ge, K.; Thiele, C. J. EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR Cancer Res. 2012, 72, 315-324
25. Cho, M.; Choi, E.; Kim, J. H.; Kim, H.; Kim, H. M.; Lee, J. I.; Hwang, K. C.; Kim, H. J.; Han, G. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control ChemMedChem 2014, 9, 649-656
26. Cho, M.; Choi, E.; Yang, J. S.; Lee, C.; Seo, J. J.; Kim, B. S.; Oh, S. J.; Kim, H. M.; Lee, K.; Park, S. K.; Kwon, H. J.; Han, G. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability ChemMedChem 2013, 8, 272-279
27. Choi, E.; Lee, C.; Cho, M.; Seo, J. J.; Yang, J. S.; Oh, S. J.; Lee, K.; Park, S. K.; Kim, H. M.; Kwon, H. J.; Han, G. Property-based optimization of hydroxamate-based gamma-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles J. Med. Chem. 2012, 55, 10766-10770
28. Kim, H. J.; Park, H. D.; Kim, J. H.; Cho, J. Y.; Choi, J. Y.; Kim, J. K.; Kim, H. J.; Shin, H. I.; Ryoo, H. M. Establishment and characterization of a stable cell line to evaluate cellular Runx2 activity J. Cell. Biochem. 2004, 91, 1239-1247
29. Yoon, H. C.; Choi, E.; Park, J. E.; Cho, M.; Seo, J. J.; Oh, S. J.; Kang, J. S.; Kim, H. M.; Park, S. K.; Lee, K.; Han, G. Property based optimization of delta-lactam HDAC inhibitors for metabolic stability Bioorg. Med. Chem. Lett. 2010, 20, 6808-6811
30. Flipo, M.; Charton, J.; Hocine, A.; Dassonneville, S.; Deprez, B.; Deprez-Poulain, R. Hydroxamates: relationships between structure and plasma stability J. Med. Chem. 2009, 52, 6790-6802
31. Kim, H. M.; Oh, S. J.; Park, S. K.; Han, G.; Kim, K.; Lee, K. S.; Kang, J. S.; Nam, M.; Lee, K. In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum Xenobiotica 2008, 38, 281-293
32. Oh, S. J.; Lee, K.; Ryu, J.; Yu, H. E.; Han, G.; Park, S. K.; Kang, J. S.; Kim, H. M.; Kim, Y. C. Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats Xenobiotica 2011, 41, 155-163
33. Venkatesh, P. R.; Goh, E.; Zeng, P.; New, L. S.; Xin, L.; Pasha, M. K.; Sangthongpitag, K.; Yeo, P.; Kantharaj, E. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species Biol. Pharm. Bull. 2007, 30, 1021-1024
34. Dignam, J. D.; Lebovitz, R. M.; Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei Nucleic Acids Res. 1983, 11, 1475-1489
35. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
36. Lee, K.; Kwon, B. M.; Kim, K.; Ryu, J.; Oh, S. J.; Lee, K. S.; Kwon, M. G.; Park, S. K.; Kang, J. S.; Lee, C. W.; Kim, H. M. Plasma pharmacokinetics and metabolism of the antitumour drug candidate 2′-benzoyloxycinnamaldehyde in rats Xenobiotica 2009, 39, 255-265